Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Semaglutide users may face hidden surgery risk, ultrasound study finds

NCT ID NCT06263595

Knowledge-focused Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study used ultrasound to measure stomach contents in 94 patients before surgery, comparing those on semaglutide (a GLP-1 drug for diabetes/weight loss) to those not taking it. The goal was to see if semaglutide increases the risk of a 'full stomach' despite following fasting rules, which could lead to dangerous aspiration during anesthesia. Researchers hope the findings will help create safer fasting guidelines for these patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide
What this could lead to
If successful, this could lead to better fasting guidelines for patients on semaglutide before surgery, reducing the risk of aspiration pneumonia.
What could go wrong
This is a small, completed observational study (94 participants) that only measures stomach volume, not actual aspiration events. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

94 people

The number who actually took part.

Started

May 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Elective surgical patients meeting inclusion/exclusion criteria at the South Health Campus (Calgary, AB, Canada)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * all elective surgical patients (\> 18 years of age) * followed institutional fasting protocol for surgery * patients taking GLP-1 receptor agonist (subcutaneous for weight management and/or blood glucose control in type II diabetes mellitus, N = 45) * patients not taking GLP-1 receptor agonist (N =45) Exclusion Criteria: * confounding delayed gastric emptying due to pregnancy * previous esophageal or gastric operation * etiologies at increased risk for delayed gastric emptying (hiatal hernia, Parkinson's disease, scleroderma, multiple sclerosis, and amyloidosis) * on medication that could potentially cause gastroparesis or delayed gastric or intestinal emptying (opioids, proton pump inhibitors, tricyclic antidepressants, calcium channel blockers, antipsychotic medications, loperamide, diphenoxylate, oxybutynin, hyoscine butylbromide, scopolamine, promethazine, glycopyrrolate, atropine, chlordiazepoxide, and lithium)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary aspiration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aspiration pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary aspiration

Contacts and locations

Locations

  • South Health Campus

    Calgary, Alberta, T3M 1M4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.